Scientists develop new blood test to identify individuals at high risk of developing hypertrophic cardiomyopathy, most common ...

The FDA has approved aficamten (Myqorzo; Cytokinetics), a cardiac myosin inhibitor, for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). 1 ...

Please provide your email address to receive an email when new articles are posted on . Few therapies have improved symptoms for patients with nonobstructive hypertrophic cardiomyopathy. In a small ...

The drug is the second cardiac myosin inhibitor to get regulatory signoff in the United States, following mavacamten in 2022.

LISBON, Portugal — A novel oral drug offers clinically meaningful improvements in exercise capacity in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) and reduces the burden of ...

Slated for a Dec. 26 decision on Cytokinetics’ aficamten, the FDA has delivered an early Christmas present, awarding the South San Francisco biotech its first U.S. nod since its 1997 founding. | ...

Scientists are developing a blood test to identify individuals at high risk for hypertrophic cardiomyopathy (HCM), the ...

Hypertrophic cardiomyopathy is the most common hereditary heart disease worldwide. An international research team is now ...

But if you have HCM, you can make a number of lifestyle choices to protect your heart health and enjoy a high quality of life. Heavy lifting is potentially risky when you’re living with HCM, because ...

Cytokinetics announced the FDA approval of aficamten to improve functional capacity and symptoms in adults with symptomatic obstructive hypertrophic cardiomyopathy.The agency approved 5 mg, 10 mg, 15 ...